Schizophrenia is a leading cause of global disability. Current pharmacotherapy for the
disease predominantly uses one mechanism—dopamine D2 receptor blockade—but often …

Ulotaront is a trace amine-associated receptor 1 (TAAR1) agonist in Phase 3 clinical
development for the treatment of schizophrenia. Ulotaront was discovered through a unique …

Elevated dopamine transmission in psychosis is assumed to unbalance striatal output
through D1-and D2-receptor-expressing spiny-projection neurons (SPNs). Antipsychotic …

Trace-amine-associated receptors (TAARs), a group of biogenic amine receptors, have
essential roles in neurological and metabolic homeostasis. They recognize diverse …

Trace amines, a group of amines expressed at the nanomolar level in the mammalian brain,
can modulate monoamine transmission. The discovery of and the functional research on the …

Aberrant dopaminergic and glutamatergic function, particularly within the striatum and
hippocampus, has repeatedly been associated with the pathophysiology of schizophrenia …

Abstract Objective Metabolic Syndrome, which can be induced or exacerbated by current
antipsychotic drugs (APDs), is highly prevalent in schizophrenia patients. Recent preclinical …

Abstract Background and Hypothesis Type-1 trace amine-associated receptors (TAAR1)
modulate dopaminergic and glutamatergic neurotransmission and are targeted by novel …

Parkinson disease (PD) psychosis (PDP) is a spectrum of illusions, hallucinations and
delusions that are associated with PD throughout its disease course. Psychotic phenomena …

Schizophrenia is a severe psychiatric illness affecting almost 25 million people worldwide
and is conceptualized as a disorder of synaptic plasticity and brain connectivity …